Kenneth Washburn, Elizabeth Pomfret, John Roberts – 1 June 2011 – Recent discussions about the distribution of cadaveric liver allografts for transplantation have raised many important issues. Over the past 2 years, a deliberative process including discussions, modeling, a request for information, a public forum, and a concept document has led to a greater focus on a possible path for reducing wait‐list mortality. Here we describe that process, our interpretation of the feedback and responses, and possible recommendations. Liver Transpl 17:1005–1012, 2011. © 2011 AASLD.

Nadezda Apostolova, Leysa J. Gomez‐Sucerquia, Anna Gortat, Ana Blas‐Garcia, Juan V. Esplugues – 29 May 2011 – Hepatotoxicity is a very common side effect associated with the pharmacological treatment of human immunodeficiency virus (HIV) infection and its pathogenesis is poorly understood. Efavirenz (EFV) is the most widely used nonnucleoside reverse transcriptase inhibitor administered for the control of HIV and some of its toxic effects in hepatic cells have been recently shown to display features of mitochondrial dysfunction.

Amanda LoGuidice, Urs A. Boelsterli – 29 May 2011

Heather L. Van Sweringen, Nozomu Sakai, Amit D. Tevar, Justin M. Burns, Michael J. Edwards, Alex B. Lentsch – 29 May 2011 – The process of liver repair and regeneration following hepatic injury is complex and relies on a temporally coordinated integration of several key signaling pathways. Pathways activated by members of the CXC family of chemokines play important roles in the mechanisms of liver repair and regeneration through their effects on hepatocytes. However, little is known about the signaling pathways used by CXC chemokine receptors in hepatocytes.

Nobuhiko Hiraga, Michio Imamura, Hiromi Abe, C. Nelson Hayes, Tomohiko Kono, Mayu Onishi, Masataka Tsuge, Shoichi Takahashi, Hidenori Ochi, Eiji Iwao, Naohiro Kamiya, Ichimaro Yamada, Chise Tateno, Katsutoshi Yoshizato, Hirotaka Matsui, Akinori Kanai, Toshiya Inaba, Shinji Tanaka, Kazuaki Chayama – 29 May 2011 – Telaprevir is a potent inhibitor of hepatitis C virus (HCV) NS3‐4A protease.

Zong‐Gen Peng, Xue‐Fu You, Jian‐Dong Jiang – 29 May 2011

Alessandra Mangia, Alexander J. Thompson, Rosanna Santoro, Valeria Piazzolla, Massimiliano Copetti, Nicola Minerva, Daniela Petruzzellis, Leonardo Mottola, Donato Bacca, John G. McHutchison – 29 May 2011

Ruben Ramirez, Jonathan C. Cohen, Helen H. Hobbs, Jeffrey D. Browning – 29 May 2011

Le‐xing Yu, He‐xin Yan, Wen Yang, Hong‐yang Wang – 29 May 2011

Joanna K. Dowman, Bridget K. Gunson, Darius F. Mirza, Simon R. Bramhall, Mike N. Badminton, Philip N. Newsome, on behalf of the UK Liver Selection and Allocation Working Party – 26 May 2011 – Acute intermittent porphyria (AIP) is an autosomal‐dominant condition resulting from a partial deficiency of the ubiquitously expressed enzyme porphobilinogen deaminase. Although its clinical expression is highly variable, a minority of patients suffer recurrent life‐threatening neurovisceral attacks despite optimal medical therapy.